1999
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol M, Olek M, Orav E, Stazzone L, Hafler D, Khoury S, Dawson D, Weiner H. Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease. Multiple Sclerosis Journal 1999, 5: 403-409. PMID: 10618696, DOI: 10.1177/135245859900500i606.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisDuration of progressionMultiple sclerosisProgressive diseaseSecondary progressive multiple sclerosisDuration of MSPrimary progressive patientsProgressive MS patientsPositive clinical responseOpen-label fashionClinical outcome measuresStart of treatmentOnset of diseaseMethylprednisolone therapySecondary progressiveImmunomodulatory treatmentImmunosuppressive therapyProgressive patientsClinical responsePatient characteristicsMS patientsImmunosuppressive agentsAutoimmune diseasesLabel fashionEDSS change
1984
Altered blood T-cell subsets in patients with multiple sclerosis
Weiner H, Hafler D, Fallis R, Johnson D, Ault K, Hauser S. Altered blood T-cell subsets in patients with multiple sclerosis. Journal Of Neuroimmunology 1984, 6: 115-121. PMID: 6373819, DOI: 10.1016/0165-5728(84)90032-8.Peer-Reviewed Original ResearchConceptsT cell subsetsMultiple sclerosisBlood T cell subsetsChronic progressive patientsActive multiple sclerosisStage of illnessSpontaneous immunoglobulin productionCentral nervous systemImmunoregulatory abnormalitiesT8 ratioActive diseaseDisease activityProgressive patientsAcute patientsPeripheral bloodImmunoglobulin productionImmune functionPatientsNervous systemSclerosisSpinal fluidDiagnostic testsAbnormalitiesVariety of protocolsPleocytosis